Clemedi develops diagnostics for infectious diseases by integrating DNA sequencing with proprietary software algorithms. Their platform rapidly analyzes drug resistance markers directly from patient samples, providing comprehensive antibiotic susceptibility profiles faster than traditional culture methods. This targeted diagnostic approach enables clinicians to prescribe effective antibiotics precisely, thereby reducing overall antibiotic consumption.
Funding
$40K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The rise of antimicrobial resistance, driven by antibiotic misuse, poses a significant threat to global health. Current diagnostic methods for infectious diseases often rely on bacterial culture, which can be slow and may not provide comprehensive information on drug resistance. This can lead to inappropriate antibiotic prescriptions, further exacerbating the problem.
Solution
Clemedi offers diagnostic solutions for infectious diseases, leveraging DNA sequencing and intelligent software to rapidly identify pathogens and their resistance to antibiotics directly from patient samples. Their flagship product, Tuberculini, detects drug-resistant tuberculosis and provides resistance testing to 12 antibiotics within 48 hours. By delivering detailed drug-susceptibility information, Clemedi enables targeted antibiotic therapy, reducing the misuse of antibiotics and combating the spread of antimicrobial resistance. The platform analyzes more resistance markers than other tests on the market and predicts antibiotic susceptibility without bacterial culture.
Target Audience
Clemedi's primary customers are laboratories and distributors seeking advanced diagnostic tools for infectious diseases, as well as healthcare providers aiming to optimize antibiotic prescriptions and combat antimicrobial resistance.
Features
- Detects drug-resistant tuberculosis and provides lineage determination directly from sputum samples in 48 hours.
- Resistance testing to 12 antibiotics.
- Analysis of more resistance markers than any other test on the market.
- Prediction of antibiotic susceptibility without bacterial culture.
- Highly multiplex PCR for amplifying regions associated with drug resistance.
- Sequencing using the Iontorrent S5 platform.
- Smart software for analyzing sequencing data and generating reports.
- Reports include pathogen identification and a full drug-susceptibility table.